Original Wu Yue Minenet
Highlights
On April 23, the NMPA official website released the latest drug approval information, Hainan Huluwa Pharmaceutical Group's terbutaline sulfate nebulized inhalation solution was approved and regarded as a review, which is the company's first listed chemical drug inhaler. In 2022, at the end of China's public medical institutions, the sales of terbutaline sulfate nebulized inhalation solution exceeded 1.2 billion yuan.
Figure 1: Huluwa Pharmaceutical's latest approved product
Source: NMPA official website
Tebutaline sulfate nebulized inhalation solution is used to relieve bronchospasm complicated by bronchial asthma, chronic bronchitis, emphysema and other lung diseases, including adults and children.
Figure 2: Sales of terbutaline sulfate nebulized inhalation solution (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
In 2022, terbutaline sulfate nebulized inhalation solution is the TOP4 product in the terminal obstructive tracheal disease drug market in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), with sales of more than 1.2 billion yuan.
Figure 3: Huluwa Pharmaceutical's approved respiratory system chemical drugs
Source: Minenet China Listed Drugs (MID) Database
According to the data of Minenet, at present, Huluwa Pharmaceutical and its subsidiaries have more than 10 respiratory system chemical drugs approved, among which terbutaline sulfate nebulized inhalation solution is the company's first approved product in this category of market this year, and it is also the company's first listed chemical drug inhaler, which is of positive significance.
Table 1: Huluwa Pharmaceutical Co., Ltd. reported the production of new respiratory system chemical drugs under review
Source: Minenet China Declaration Progress (MED) database
At present, Huluwa Pharmaceutical still has 11 new respiratory system chemical drugs under review, of which 5 are inhalers, including acetylcysteine solution for inhalation, ipratropium bromide solution for inhalation, levalbuterol hydrochloride nebulized inhalation solution, compound ipratropium bromide solution for inhalation and albuterol sulfate solution for inhalation.
In the terminal chemical drugs (including biological drugs) market of China's public medical institutions, the sales scale of inhalants will remain above 20 billion yuan in 2022, and Huluwa Pharmaceutical may become a new dark horse in this market.
Source: Minenet database, NMPA official website
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics, and the above sales are calculated based on the average retail price of products at the terminal. Statistics as of April 24, if there is any omission, please correct!